Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
50P - The expression and significance of miR-146a and miR-146b in BALB/c mice pulmonary precancerous lesions induced by fine particulate matter (ID 235)
12:30 - 13:00 | Presenting Author(s): T. Hou
Lung cancer is one of the commonest malignant tumors threatening the health of human being. The morbidity and mortality of lung cancer increased rapidly, early detection and early treatment is the key to increase the survival rate of lung cancer patients. Studies have confirmed that air pollution is closely related to the occurrence of lung cancer. Air pollution (mainly PM2.5) has been classified as a carcinogen by the International Agency for Research on Cancer. MicroRNAs (miRNAs) are endogenous, noncoding RNAs consisting of 21–23 nucleotides which are stable existence in the blood. It is one kind of potential diagnostic markers in serum. In order to verify whether microRNA-146 can be used as early warning indicators of precancerous lesion of lung cancer.
30 BALB/c mice were treated with noninvasive tracheal instillation of fine particulate matter suspension at different doses for 90 days (two times one week), histopathological changes, pro-infammatory factors levels, pulmonary functions and the relative expression of microRNA-146 were detected.
Histopathological changes showed atypical hyperplasia of alveolar epithelial cells, alveolar macrophages with engulfed particles and lymphocyte aggregation in bronchiole and alveolar. Pro-inflammatory factors IL-6, IFN-γ and TNF-α were increased significantly, however, PIF and PEF were decreased significantly. Lung resistance Increased and MVV reduced from the general tendency, the relative expressions of miR-146a and miR-146b were up-regulated remarkably in treatment groups compared to the control group.
MiR-146a and miR-146b may be novel warning biomarkers for early detection of pulmonary precancerous lesions.
Clinical trial identification:
Legal entity responsible for the study:
Peking University First Hopital
Beijing Municipal Natural Science Foundation (Key Program: No.7161013)
All authors have declared no conflicts of interest.